Tuesday, October 2, 2012

ARQULE AND DAIICHI SANKYO ANNOUNCE DISCONTINUATION OF PHASE 3 MARQUEE CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER

Based on an interim analysis, the Data monitoring committee recommended discontinuation of the trial for lack of benefit in terms of  improving the median overall survival. MARQUEE is a randomized, double-blind, controlled pivotal trial to evaluate the investigational selective MET inhibitor, tivantinib (ARQ 197), in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous NSCLC.
There were no Unexpected Safety Findings from Interim Analysis.